Search LFVN
Lifevantage Corp
Nasdaq · CIK 849146
Last close6.07
Daily change-0.17 (-2.72%)
10 Years gain-27.94%
Dividends TTM0.19 (+11.76%)
Dividend yield3.04%
Fundamental Analysis
LFVN · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 0630
Fundamental
52.4Momentum
55.8Acceleration
73.5Confidence
95.0Annual Revenue16
Quarterly Revenue71
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth4.1 / 25
Quality9.0 / 25
Capital Efficiency20.0 / 20
Balance Sheet14.8 / 15
Shareholder Economics4.5 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 1.1668 percentage points.
ROIC expansionROIC improved by 12.8611 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 3.9235%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
FCF deterioration · MEDIUMFree cash flow declined 58.9772%.
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
Key Metrics
Revenue Growth TTM-7.54%OK
Revenue CAGR 3Y-5.07%OK
Gross Margin78.48%OK
Operating Margin4.27%OK
FCF Margin2.44%OK
FCF Growth-58.98%OK
ROIC28.41%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFO-1.62xOK
Diluted Share Growth 1Y-3.92%OK
SBC / Revenue1.81%OK
SBC / FCF74.51%OK
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 FY Jun 30, 2026 | $182.59M | $141.61M | $6.10M | $10.24M | $6.67M | 77.56% | 3.34% | 3.65% | 30.81% | 12.7M |
| 2026 FY Jun 30, 2025 | $228.53M | $183.67M | $12.20M | $11.88M | $10.51M | 80.37% | 5.34% | 4.6% | 82.99% | 12.99M |
| 2025 FY Jun 30, 2024 | $200.16M | $158.72M | $4.33M | $12.20M | $9.95M | 79.3% | 2.16% | 4.97% | 26.41% | 12.99M |
| 2024 FY Jun 30, 2023 | $213.40M | $170.01M | $4.26M | $6.83M | $3.76M | 79.67% | 2% | 1.76% | 22.72% | 12.57M |
| 2023 FY Jun 30, 2022 | $206.36M | $168.26M | $7.58M | $7.96M | $6.43M | 81.54% | 3.67% | 3.12% | 40.37% | 13.07M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $198.65M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-208922, 0001628280-25-048792 |
| Revenue Growth TTM | -7.54% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-208922, 0001628280-25-048792 |
| Revenue CAGR 3Y | -5.07% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-371257 |
| Revenue CAGR 5Y | -3.68% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-371257 |
| Gross Profit CAGR 3Y | -5.91% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-371257 |
| Operating Income Growth | 27.21% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001193125-26-208922, 0001628280-25-048792 |
| FCF Growth | -58.98% | FCF_current / FCF_prior_year - 1 | OK | 0001193125-26-208922, 0001628280-26-005428 |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 78.48% | Gross Profit / Revenue | OK | 0001193125-26-208922, 0001628280-25-048792 |
| Operating Margin | 4.27% | Operating Income / Revenue | OK | 0001193125-26-208922, 0001628280-25-048792 |
| FCF Margin | 2.44% | (CFO - CapEx) / Revenue | OK | 0001193125-26-208922, 0001628280-26-005428 |
| ROIC | 28.41% | NOPAT / Average Invested Capital | OK | 0001193125-26-208922, 0001628280-25-048792 |
| Net Debt / CFO | -1.62x | Net Debt / CFO | OK | 0001193125-26-208922, 0001628280-26-005428 |
| Current Ratio | 1.96x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 1.81% | SBC / Revenue | OK | 0001193125-26-208922, 0001628280-26-005428 |